

## Changed date for Year End Report

The board of Q-linea AB (publ) ("Q-linea" or the "Company") has decided to change the date for the Year End Report.

The background to the board's decision is the ongoing recruitment process of new CEO that was initiated and announced via a separate press release, meaning that the board found it most appropriate to postpone the Year End Report. Q-linea's Year End Report for 2023 will be published Tuesday, February 27, 2024 at 7.30 a.m.

### For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB

[Jonas.Jarvius@qlinea.com](mailto:Jonas.Jarvius@qlinea.com)

+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB

[Christer.Samuelsson@qlinea.com](mailto:Christer.Samuelsson@qlinea.com)

+46 (0) 70-600 15 20

### About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit [www.qlinea.com](http://www.qlinea.com).

### Attachments

[Changed date for Year End Report](#)